LARVOL Competitive Intelligence & Landscape

LARVOL (larvol.com) is a leading provider of expert data solutions for pharmaceutical and biotech companies, specializing in oncology data intelligence and AI. Established in 2004, LARVOL offers comprehensive intelligence, analysis, and software solutions designed to accelerate breakthroughs in oncology. The company's mission is to help top pharma and biotech companies navigate the complexities of cancer research and drug development by providing access to one of the largest oncology datasets in the industry. This dataset spans over 100,000 cancer clinical trials, 6,000 oncologists on social media, 4,500 products, 1,850 mechanisms of action (MOAs), 400 biomarkers, and 900 diagnostic tests.

LARVOL provides a suite of core products and services including CLIN, PULSE, CONF, and REDRAW.

CLIN is an AI-powered oncology data and insights platform offering access to over 100,000 cancer clinical trials with detailed results, analysis tools, and social media reactions from top Key Opinion Leaders (KOLs).

PULSE delivers concise, up-to-date reports on drug development and industry trends directly to users.

CONF assists with conference planning by providing a customized planner that indexes abstracts, posters, and presentations by MOAs, products, and diseases of interest, along with post-conference recaps. Additionally, REDRAW offers specialized data redraw services for clinical trial figures from oncology conference coverage.

The target market for LARVOL includes the largest pharmaceutical, biotech, and healthcare companies globally. The company prides itself on being trusted by top pharma companies, offering customized intelligence and software solutions. Headquartered in San Francisco, CA, LARVOL is a growing global team of over 170 dedicated experts with deep clinical and industry expertise. Their team comprises proactive industry experts who often work remotely, fostering a self-guided work environment that contributes to their exceptional results and comprehensive offerings for the competitive intelligence needs of the life science industry.

LARVOL is a leading provider of expert data solutions for the pharma and biotech industries, specializing in oncology data intelligence. The company offers a suite of products designed to accelerate breakthroughs by providing access to comprehensive clinical trial data, market intelligence, and expert analysis. Their platform integrates over 100,000 cancer trials, social media reactions from over 6,000 oncologists, and data on thousands of products, MOAs, biomarkers, and diagnostic tests. While LARVOL offers a 30-day free trial for its main platform, specific pricing for its various solutions typically requires a demo request.

Key LARVOL products include CLIN, an AI-powered platform for cancer trial results with over 100,000 cancer clinical trials and expert curation; PULSE, which delivers concise, up-to-date reports on drug development and industry trends from over 25,000 sources; and CONF, a customized conference planner that organizes sessions and abstracts by disease, products, and MOAs, delivered within 36 hours.

LARVOL also offers REDRAW for clinical trial data figure redrawing and IMPACT for expert trend analysis from digital opinion leaders. Pricing for these specialized services is generally available upon request for a demo.

LARVOL also provides VERI, a precision oncology database launched in 2020 that links cancer biomarkers to drug/MOA responses.

VERI is free for non-commercial or academic research use, while commercial use requires a paid license, which can be explored by contacting LARVOL for details on premium content like news alerts, weekly reports, and conference planners. Another offering, LARVOL SIGMA, is a clinical trial and pipeline intelligence platform with over 11,000 drugs and 150,000 clinical trials, available with a 14-day free trial. The company also launched OMNI in 2022, a next-gen KOL and pharma tracking tool that provides custom weekly reports on KOL news, events, analytics, and Sunshine payment data, with pricing details typically provided after a demo request.

LARVOL demonstrates a strategic commitment to expansion, emphasizing remote work flexibility and a global talent acquisition approach. The company, which has provided competitive intelligence and software solutions to major pharmaceutical and biotech firms since 2004, actively seeks to grow its team of "proactive industry experts." This strategy allows LARVOL to tap into a wider pool of skilled professionals who thrive in a self-guided, remote environment, as highlighted on their careers page [https://www.larvol.com/careers-at-larvol]. This hiring pattern signals an intent to scale operations and enhance its service offerings without geographical constraints.

Recent job postings from September 13, 2021, reveal a concentrated effort to bolster key areas of the business.

LARVOL has been actively recruiting for high-impact roles such as a VP of Sales [https://www.larvol.com/career/sales-vp] and a Head of Marketing [https://www.larvol.com/career/marketing-head], both crucial for driving revenue growth and expanding market presence. Additionally, the company sought a Business Development Representative for both the Americas and Europe [https://www.larvol.com/career/business-development-representative] and an Account Executive for the Americas [https://www.larvol.com/career/account-executive], indicating a push to expand its client base and strengthen its sales pipeline globally.

Beyond sales and marketing, LARVOL has also focused on enhancing its core data analysis capabilities. Job openings for a Regex Associate Analyst [https://www.larvol.com/career/regex-associate-analyst] and a Biomarker Research Analyst [https://www.larvol.com/career/biomarker-research-analyst] (both contract roles) underscore the company's continuous need for specialists to extract, analyze, and categorize intricate clinical trial information. This sustained investment in analytical talent is vital for maintaining the depth and accuracy of their oncology dataset, which is a cornerstone of their competitive intelligence solutions. While no layoffs have been publicly announced, the consistent hiring in critical departments, including the appointment of Mark Lagunowich as Vice President, Global Sales in February 2021 [https://www.larvol.com/blog/larvol-appoints-new-vice-president-global-sales], suggests a growth-oriented strategy aimed at solidifying its position as a leader in oncology data intelligence.

LARVOL, a company specializing in expert data solutions for the pharma and biotech industries, has been a significant player since its inception in 2004. The company provides customized intelligence and software solutions to major pharmaceutical, biotech, and healthcare organizations globally, indicating a consistent revenue stream from a high-value client base [larvol.com/about-larvol]. While specific revenue figures are not publicly disclosed, the company's continuous operation and expansion suggest a healthy financial performance, underpinned by its role in accelerating breakthroughs in oncology through data intelligence and AI [larvol.com].

Although details regarding specific fundraising rounds, valuations, or M&A activities are not explicitly mentioned in the provided sources, LARVOL's sustained growth and investment in innovative technologies like AI-powered oncology data intelligence point to a financially stable and forward-thinking organization. The launch of platforms such as CLIN in 2021, which curates historical clinical trial data, and PULSE for market intelligence, demonstrates ongoing product development and an ability to invest in expanding its offerings to meet industry demands [larvol.com/blog/larvol-launches-platform-to-curate-historical-active-immuno-oncology-clinical-trial-data-in-digital-dashboard].

LARVOL's operational structure also reflects a strategic approach to financial management and growth. With a global team of over 170 dedicated experts and a remote-first work model, the company optimizes operational costs while attracting top talent [larvol.com/about-larvol]. The move of its corporate headquarters to the metaverse in 2020, championed by CEO Bruno Larvol, highlights an experimental and potentially cost-effective approach to business operations and collaboration, further demonstrating innovative financial and operational strategies [larvol.com/blog/our-shift-to-the-metaverse-a-conversation-with-ceo-bruno-larvol]. This commitment to leveraging emerging technologies for internal operations, alongside its core business of delivering critical data solutions, suggests a company focused on long-term financial health and efficiency.

LARVOL actively participates in and hosts various events, webinars, and conferences, demonstrating its commitment to the oncology and pharmaceutical communities. The company frequently attends major industry gatherings such as ASCO (American Society of Clinical Oncology), with planned attendance at ASCO 2026 in Chicago Meet LARVOL At ASCO 2026: May 29 - June 2 | Chicago, IL 🇺🇸 | Oncology News & Trial Updates | CLIN by Larvol, where they also engage in live podcasts covering oncology trends and clinical trials Ep 29 | Pre ASCO 2026 – Live from Times Square. Additionally, LARVOL is a regular participant at ESMO (European Society for Medical Oncology) events, including ESMO TAT 2026 LARVOL Will Be Attending ESMO TAT 2026 | Oncology News & Trial Updates | CLIN by Larvol and ESMO Breast Cancer 2026 Ep 28 | Live from ESMO Breast Cancer 2026. The company also has a presence at the San Antonio Breast Cancer Symposium (SABCS), with plans to attend SABCS 2025 LARVOL Will Be At SABCS 2025 | Oncology News & Trial Updates | CLIN by Larvol. These participations allow LARVOL to share clinical research and engage with oncology thought leaders.

LARVOL extends its engagement beyond attendance by hosting insightful webinars and interactive sessions. For instance, they hosted the "ASCO 2021 Clinical Panel Series - Genitourinary Cancer" webinar in June 2021, featuring discussions with expert panelists on top GU cancer abstracts from ASCO LARVOL | Events. During ASCO 2021, LARVOL not only presented a clinical research poster but also hosted a virtual reality-based “Night at the Museum” event to recognize top oncologist influencers ·Present clinical research poster at ASCO. This demonstrates LARVOL’s innovative approach to engaging the scientific community.

The company also provides valuable resources to assist attendees with conference planning, offering a free AACR 2025 Conference Planner to help streamline the navigation of complex programs and key updates Streamline Your AACR 2025 Planning with Our Free Conference Planner!. This initiative, part of their CONF solutions, offers customized planners for various pharma and medical conferences, organizing sessions and abstracts by diseases, products, and MOAs LARVOL | CONF - Customized Pharma And Medical Conference Planners. Furthermore, LARVOL attends and plans to attend key industry conferences like the Pharma CI Conference - USA 2025 Attending Pharma CI Conference - USA 2025? Meet the LARVOL team in Newark, NJ!, underscoring their active involvement in the competitive intelligence landscape within the pharmaceutical sector. Through these diverse events and offerings, LARVOL consistently fosters engagement and facilitates knowledge sharing within the oncology, pharmaceutical, and biotech industries.